In patients with advanced solid tumors or lymphoma.

AEterna Zentaris presents outcomes for AEZS-112 in advanced lymphoma and cancer AEterna Zentaris Inc. Has provided a poster outlining Stage 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially give a new therapeutic strategy for the treating cancer . The poster was presented at the American Association for Tumor Research Annual Getting together with in Denver, Colorado. The poster entitled, Stage I dose-escalation, basic safety, and pharmacokinetic research on every week oral AEZS-112, a small molecule anti-malignancy agent in patients with advanced lymphoma and cancer, D.W.